Annual Long Term Debt
$595.14 M
+$2.04 M+0.34%
December 31, 2024
Summary
- As of February 26, 2025, BMRN annual long term debt is $595.14 million, with the most recent change of +$2.04 million (+0.34%) on December 31, 2024.
- During the last 3 years, BMRN annual long term debt has fallen by -$483.94 million (-44.85%).
- BMRN annual long term debt is now -45.05% below its all-time high of $1.08 billion, reached on December 31, 2022.
Performance
BMRN Long Term Debt Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Long Term Debt
$595.14 M
+$511.00 K+0.09%
December 31, 2024
Summary
- As of February 26, 2025, BMRN quarterly long term debt is $595.14 million, with the most recent change of +$511.00 thousand (+0.09%) on December 31, 2024.
- Over the past year, BMRN quarterly long term debt has increased by +$511.00 thousand (+0.09%).
- BMRN quarterly long term debt is now -48.96% below its all-time high of $1.17 billion, reached on September 30, 2017.
Performance
BMRN Quarterly Long Term Debt Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Long Term Debt Formula
Long-Term Debt = Bonds Payable + Long-Term Loans + Mortgage Payable + Other Long-Term Borrowings − Current Portion of Long-Term Debt
BMRN Long Term Debt Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +0.3% | +0.1% |
| 3 y3 years | -44.9% | -45.1% |
| 5 y5 years | +22.4% | -45.1% |
BMRN Long Term Debt Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -45.0% | +0.3% | -45.1% | +0.4% |
| 5 y | 5-year | -45.0% | +22.4% | -45.1% | +22.4% |
| alltime | all time | -45.0% | >+9999.0% | -49.0% | >+9999.0% |
BioMarin Pharmaceutical Long Term Debt History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $595.14 M(+0.3%) | $595.14 M(+0.1%) |
| Sep 2024 | - | $594.63 M(+0.1%) |
| Jun 2024 | - | $594.12 M(+0.1%) |
| Mar 2024 | - | $593.61 M(+0.1%) |
| Dec 2023 | $593.10 M(-45.2%) | $593.10 M(+0.1%) |
| Sep 2023 | - | $592.59 M(-45.4%) |
| Jun 2023 | - | $1.08 B(+0.1%) |
| Mar 2023 | - | $1.08 B(+0.1%) |
| Dec 2022 | $1.08 B(+0.4%) | $1.08 B(+0.1%) |
| Sep 2022 | - | $1.08 B(+0.1%) |
| Jun 2022 | - | $1.08 B(+0.1%) |
| Mar 2022 | - | $1.08 B(+0.1%) |
| Dec 2021 | $1.08 B(+0.4%) | $1.08 B(+0.1%) |
| Sep 2021 | - | $1.08 B(+0.1%) |
| Jun 2021 | - | $1.08 B(+0.1%) |
| Mar 2021 | - | $1.08 B(+0.1%) |
| Dec 2020 | $1.08 B(+121.1%) | $1.08 B(+0.1%) |
| Sep 2020 | - | $1.07 B(+0.1%) |
| Jun 2020 | - | $1.07 B(+120.5%) |
| Mar 2020 | - | $486.71 M(+0.1%) |
| Dec 2019 | $486.24 M(-41.4%) | $486.24 M(-42.4%) |
| Sep 2019 | - | $843.62 M(+0.5%) |
| Jun 2019 | - | $839.16 M(+0.5%) |
| Mar 2019 | - | $834.77 M(+0.5%) |
| Dec 2018 | $830.42 M(+2.1%) | $830.42 M(+0.5%) |
| Sep 2018 | - | $826.12 M(+0.5%) |
| Jun 2018 | - | $821.87 M(+0.5%) |
| Mar 2018 | - | $817.67 M(+0.5%) |
| Dec 2017 | $813.52 M(+23.1%) | $813.52 M(-30.2%) |
| Sep 2017 | - | $1.17 B(+72.4%) |
| Jun 2017 | - | $676.21 M(+1.2%) |
| Mar 2017 | - | $668.44 M(+1.2%) |
| Dec 2016 | $660.76 M(-0.2%) | $660.76 M(+1.2%) |
| Sep 2016 | - | $653.18 M(+1.2%) |
| Jun 2016 | - | $645.68 M(-3.3%) |
| Mar 2016 | - | $668.01 M(+0.9%) |
| Dec 2015 | $662.29 M(+3.0%) | $662.29 M(-0.8%) |
| Sep 2015 | - | $667.79 M(+1.0%) |
| Jun 2015 | - | $661.49 M(+0.9%) |
| Mar 2015 | - | $655.49 M(+2.0%) |
| Dec 2014 | $642.90 M(-1.9%) | $642.90 M(-2.1%) |
| Sep 2014 | - | $656.88 M(+0.9%) |
| Jun 2014 | - | $650.87 M(-1.6%) |
| Mar 2014 | - | $661.42 M(+0.9%) |
| Dec 2013 | $655.57 M(+101.8%) | $655.57 M(+737.1%) |
| Sep 2013 | - | $78.31 M(-28.7%) |
| Jun 2013 | - | $109.82 M(-0.0%) |
| Mar 2013 | - | $109.85 M(-66.2%) |
| Dec 2012 | $324.86 M | $324.86 M(-0.0%) |
| Sep 2012 | - | $324.86 M(-0.0%) |
| Jun 2012 | - | $324.87 M(-0.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2012 | - | $324.87 M(-6.7%) |
| Dec 2011 | $348.33 M(-7.7%) | $348.33 M(-0.0%) |
| Sep 2011 | - | $348.34 M(-7.7%) |
| Jun 2011 | - | $377.52 M(-0.0%) |
| Mar 2011 | - | $377.52 M(0.0%) |
| Dec 2010 | $377.52 M(-24.1%) | $377.52 M(-29.2%) |
| Sep 2010 | - | $533.41 M(+2.3%) |
| Jun 2010 | - | $521.24 M(-0.7%) |
| Mar 2010 | - | $524.86 M(+5.6%) |
| Dec 2009 | $497.08 M(0.0%) | $497.08 M(0.0%) |
| Sep 2009 | - | $497.08 M(0.0%) |
| Jun 2009 | - | $497.08 M(0.0%) |
| Mar 2009 | - | $497.08 M(0.0%) |
| Dec 2008 | $497.08 M(-0.1%) | $497.08 M(-0.0%) |
| Sep 2008 | - | $497.24 M(-0.0%) |
| Jun 2008 | - | $497.25 M(-0.0%) |
| Mar 2008 | - | $497.30 M(-0.0%) |
| Dec 2007 | $497.38 M(+122.1%) | $497.38 M(-11.9%) |
| Sep 2007 | - | $564.32 M(-0.1%) |
| Jun 2007 | - | $564.71 M(+134.9%) |
| Mar 2007 | - | $240.44 M(+7.4%) |
| Dec 2006 | $223.94 M(+5.2%) | $223.94 M(-23.6%) |
| Sep 2006 | - | $293.08 M(-20.2%) |
| Jun 2006 | - | $367.31 M(-0.1%) |
| Mar 2006 | - | $367.84 M(+72.8%) |
| Dec 2005 | $212.92 M(-6.6%) | $212.92 M(-0.7%) |
| Sep 2005 | - | $214.45 M(-0.7%) |
| Jun 2005 | - | $215.97 M(+49.4%) |
| Mar 2005 | - | $144.60 M(-36.6%) |
| Dec 2004 | $228.04 M(+82.4%) | $228.04 M(+2.7%) |
| Sep 2004 | - | $222.06 M(+72.4%) |
| Jun 2004 | - | $128.78 M(+3.0%) |
| Mar 2004 | - | $125.00 M(0.0%) |
| Dec 2003 | $125.00 M(+3055.8%) | $125.00 M(0.0%) |
| Sep 2003 | - | $125.00 M(0.0%) |
| Jun 2003 | - | $125.00 M(+4192.6%) |
| Sep 2002 | - | $2.91 M(-16.9%) |
| Mar 2002 | - | $3.50 M(-11.6%) |
| Dec 2001 | $3.96 M(+6973.2%) | $3.96 M(+2613.0%) |
| Sep 2001 | - | $146.00 K(-26.3%) |
| Jun 2001 | - | $198.00 K(+321.3%) |
| Mar 2001 | - | $47.00 K(-16.1%) |
| Dec 2000 | $56.00 K(-34.1%) | $56.00 K(-11.1%) |
| Sep 2000 | - | $63.00 K(-7.4%) |
| Jun 2000 | - | $68.00 K(-11.7%) |
| Mar 2000 | - | $77.00 K(-9.4%) |
| Dec 1999 | $85.00 K(-15.0%) | $85.00 K(-15.0%) |
| Sep 1999 | - | $100.00 K(-99.6%) |
| Jun 1999 | - | $26.10 M(>+9900.0%) |
| Mar 1999 | - | $100.00 K |
| Dec 1998 | $100.00 K | - |
FAQ
- What is BioMarin Pharmaceutical annual long term debt?
- What is the all time high annual long term debt for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical annual long term debt year-on-year change?
- What is BioMarin Pharmaceutical quarterly long term debt?
- What is the all time high quarterly long term debt for BioMarin Pharmaceutical?
- What is BioMarin Pharmaceutical quarterly long term debt year-on-year change?
What is BioMarin Pharmaceutical annual long term debt?
The current annual long term debt of BMRN is $595.14 M
What is the all time high annual long term debt for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high annual long term debt is $1.08 B
What is BioMarin Pharmaceutical annual long term debt year-on-year change?
Over the past year, BMRN annual long term debt has changed by +$2.04 M (+0.34%)
What is BioMarin Pharmaceutical quarterly long term debt?
The current quarterly long term debt of BMRN is $595.14 M
What is the all time high quarterly long term debt for BioMarin Pharmaceutical?
BioMarin Pharmaceutical all-time high quarterly long term debt is $1.17 B
What is BioMarin Pharmaceutical quarterly long term debt year-on-year change?
Over the past year, BMRN quarterly long term debt has changed by +$511.00 K (+0.09%)